{"url":"https://lda.senate.gov/api/v1/filings/0c2ea715-b5f8-47c0-a41d-e78c4c876b33/","filing_uuid":"0c2ea715-b5f8-47c0-a41d-e78c4c876b33","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/0c2ea715-b5f8-47c0-a41d-e78c4c876b33/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"T.J. Petrizzo, Chairman & CEO","dt_posted":"2020-01-12T16:57:18.160000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 New Jersey Ave NW","registrant_address_2":"Suite 830","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":305932,"url":"https://lda.senate.gov/api/v1/registrants/305932/","house_registrant_id":38088,"name":"THE PETRIZZO GROUP, INC.","description":"Government Relations and Strategic Communications Firm","address_1":"601 New Jersey Avenue NW","address_2":"Suite 830","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"T.J. PETRIZZO","contact_telephone":"+1 202-365-4583","dt_updated":"2026-07-20T09:24:00.173382-04:00"},"client":{"id":181819,"url":"https://lda.senate.gov/api/v1/clients/181819/","client_id":1005178,"name":"ALLENA PHARMACEUTICALS","general_description":"Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders","client_government_entity":false,"client_self_select":null,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-09-01"},"lobbying_activities":[{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"National Kidney Initiative -- Development of first in class therapeutics for patients with\nrare and severe metabolic disorders that affect the kidney.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":3241,"prefix":null,"prefix_display":null,"first_name":"TJ","nickname":null,"middle_name":null,"last_name":"PETRIZZO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68503,"prefix":null,"prefix_display":null,"first_name":"MEGAN","nickname":null,"middle_name":"CRISTINA","last_name":"PEREZ BURKE","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Congresswoman Cathy McMorris Rodgers","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"National Kidney Initiative -- Development of first in class therapeutics for patients with\nrare and severe metabolic disorders that affect the kidney.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":3241,"prefix":null,"prefix_display":null,"first_name":"TJ","nickname":null,"middle_name":null,"last_name":"PETRIZZO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}